We are currently studying a variety of tumor-derived factors with effects on tumor-associated vasculature. These include vascular endothelial growth factor (VEGF) and endothelial cell monocyte-activating polypeptide II (EMAP-II). These cytokines appear to be produced in varying amounts by tumors and have direct effects on the tumor neovasculature. Our approach to the study of these interactions has been through the utilization of a variety of in vitro and in vivo model systems. We are using gene expression profiling to understand the changes that occur in endothelial cells exposed to tumor-derived factors. The laboratory is developing techniques, which allow us to isolate endothelial cells from tumor tissue. This has resulted in our ability to study tumor-derived endothelial cells directly, and has led to our observation that tumor associated endothelial cells have epigenetic changes compared to normal endothelial cells from the same tissue type. We are also using noninvasive imaging techniques, including dynamic MRI and PET, to map changes in tumor blood flow within tumors both in animal models and in our patients on clinical trials. A variety of inhibitors of tumor angiogenesis are being actively studied. These include both recombinant proteins derived from naturally occurring substances as well as small molecules designed to act on specific pathways. Various methods of delivering these agents, including gene therapy approaches and the use of tumor targeted nanoparticles are being pursued. Our overall goal is to translate a better understanding of tumor cell-endothelial cell interactions into better therapies for our patients with cancer.
| Libutti, Steven K; Paciotti, Giulio F; Byrnes, Adriana A et al. (2010) Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res 16:6139-49 |
| He, Mei; Mangiameli, David P; Kachala, Stefan et al. (2010) Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival. Clin Cancer Res 16:249-59 |
| Shen, H-C Jennifer; He, Mei; Powell, Anathea et al. (2009) Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res 69:1858-66 |
| Prasad, Nijaguna B; Somervell, Helina; Tufano, Ralph P et al. (2008) Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res 14:3327-37 |
| Lodish, Maya B; Powell, Anathea C; Abu-Asab, Mones et al. (2008) Insulinoma and gastrinoma syndromes from a single intrapancreatic neuroendocrine tumor. J Clin Endocrinol Metab 93:1123-8 |
| Blansfield, Joseph A; Caragacianu, Diana; Alexander 3rd, H Richard et al. (2008) Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14:270-80 |
| Chung, Joon-Yong; Braunschweig, Till; Williams, Reginald et al. (2008) Factors in Tissue Handling and Processing That Impact RNA Obtained From Formalin-fixed, Paraffin-embedded Tissue. J Histochem Cytochem 56:1033-42 |
| Shen, H-C Jennifer; Rosen, Jennifer E; Yang, Lauren M et al. (2008) Parathyroid tumor development involves deregulation of homeobox genes. Endocr Relat Cancer 15:267-75 |
| He, Mei; Rosen, Jennifer; Mangiameli, David et al. (2007) Cancer development and progression. Adv Exp Med Biol 593:117-33 |
| Rodriguez-Canales, J; Hanson, J C; Tangrea, M A et al. (2007) Identification of a unique epigenetic sub-microenvironment in prostate cancer. J Pathol 211:410-9 |
Showing the most recent 10 out of 52 publications
